Antibodies against PCSK9: A new LDL-c lowering therapy?
Brief CME. An introduction by Dr. Kees Hovingh, AMC, Amsterdam about the discovery of PCSK9 and the development of antibodies as a novel strategy to reduce LDL-c.
A 3D video animation on the role of PCSK9 (with couresy of Amgen)
Advancing the Understanding of Cholesterol Metabolism:The Role of Proprotein Convertase Subtilisin-like/kexin Type 9 (PCSK9) in the Regulation of Low-Density Lipoprotein Cholesterol (LDL-C) and LDL Receptors (LDL-Rs) Read more...